Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Jianglan Long und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Biomarkers. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, the Youth Beijing Scholar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To explore biomarkers that can predict the response of type 2 diabetes (T2D) patients to metformin at an early stage to provide better treatment for T2D.
Methods
T2D patients with (responders) or without response (non‐responders) to metformin were recruited, and their serum samples were used for metabolomic analysis to identify candidate biomarkers. Moreover, the efficacy of metformin was verified by insulin‐resistant mice, and the candidate biomarkers were verified to determine the biomarkers. Five different machine learning methods were used to construct the integrated biomarker profiling (IBP) with the biomarkers to predict the response of T2D patients to metformin.
Results
A total of 73 responders and 63 non‐responders were recruited, and 88 differential metabolites were identified in the serum samples. After being verified in mice, 19 of the 88 were considered as candidate biomarkers. Next, after metformin regulation, nine candidate biomarkers were confirmed as the biomarkers. After comparing five machine learning models, the nine biomarkers were constructed into the IBP for predicting the response of T2D patients to metformin based on the Naïve Bayes classifier, which was verified with an accuracy of 89.70%.
Conclusions
The IBP composed of nine biomarkers can be used to predict the response of T2D patients to metformin, enabling clinicians to start a combined medication strategy as soon as possible if T2D patients do not respond to metformin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Dan Yan
Förderung
- the National Natural Science Foundation of China
- Capital's Funds for Health Improvement and Research
- the Youth Beijing Scholar
- National Natural Science Foundation of China
Zitieren
APA
Long, J., Fang, Q., Shi, Z., Miao, Z., & Yan, D. (2024). Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15689
Vancouver
Long J, Fang Q, Shi Z, Miao Z, Yan D. Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15689
BibTeX
@article{Long2024,
author = {Long, Jianglan and Fang, Qiushi and Shi, Zhe and Miao, Zenghui and Yan, Dan},
title = {Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15689}
}
EUVIMED